Nuwiq
Author: Daniel Chancellor
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Nuwiq (Octapharma) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A. It is a fourth-generation recombinant product produced in human embryonic kidney cells, thus eliminating any potential source of non-human mammalian proteins with antigenic potential. Nuwiq is indicated for on-demand, prophylactic, and perioperative use in both adults and children. Octapharma developed Nuwiq and has exclusively marketed the drug since 2014.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Nuwiq : Hemophilia
LIST OF FIGURES
9 Figure 11: Datamonitor Healthcare’s drug assessment summary of Advate for hemophilia
10 Figure 10: Datamonitor Healthcare’s drug assessment summary of Adynovate for hemophilia
12 Figure 12: AMT-061 for hemophilia – SWOT analysis
LIST OF TABLES
5 Table 1: Nuwiq drug profile
7 Table 2: Nuwiq pivotal trial data in hemophilia
13 Table 3: Nuwiq sales for hemophilia across the US and five major EU markets, by country ($m), 2016–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Afstyla 
Sign up to the